Commentary

Targeting CDC34 E2 ubiquitin conjugating enzyme for lung cancer therapy

Shizhen Zhang\textsuperscript{a,b}, Yi Sun\textsuperscript{a,b,*}

\textsuperscript{a} The Cancer Institute of the Second Affiliated Hospital and Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou 310029, China
\textsuperscript{b} Division of Radiation and Cancer Biology, Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109, United States

\textbf{ARTICLE INFO}

Article History:
Received 27 February 2020
Accepted 2 March 2020
Available online xxx

Protein ubiquitylation is a common post-translational modification, catalyzed by an E1 ubiquitin activating enzyme, an E2 ubiquitin-conjugating enzyme, and an E3 ubiquitin ligase. CDC34 is a common E2 responsible for assembly of the Lys48-linked polyubiquitylation chains on a substrate for proteasomal degradation [1]. While potential involvement of CDC34 in human cancer has been proposed due to its overexpression in a number of human cancers [2,3], whether CDC34 is an attractive therapeutic target, and in what type(s) of human cancer, remains elusive.

In the March 2020 issue of EBioMedicine [4], Zhao and colleagues focused on the involvement of the protein ubiquitylation pathway in controlling the growth of non-small cell lung cancer cells (NSCLCs), and identified CDC34 as a top candidate essential for cell proliferation via the functional screening of a siRNA library consisting of pooled siRNAs targeting 696 ubiquitin pathway genes. Subsequent studies confirmed that CDC34 knockdown inhibited, whereas CDC34 overexpression promoted, the growth and survival of lung cancer cells. Importantly, CDC34 was overexpressed in 66.7% of NSCLC tumor samples, and CDC34 overexpression predicted a worse prognosis of patients, implying an oncogenic role in NSCLCs. Furthermore, CDC34 is stress-responsive and induced by tobacco smoke in normal lung epithelial cells of the A/J mice. Consistently, tumors derived from smokers had higher CDC34 levels than those from nonsmokers. Taken together, these association studies strongly suggest that CDC34 could play a role in lung tumorigenesis. However, whether CDC34 is a valid lung cancer target - and what the underlying mechanism(s) of CDC34 action is - have not been systematically pursued. To this end, Zhao et al., analyzed previously published clinical data of patients with c-Cbl to mediate EGFR ubiquitylation. The ubiquitylated EGFR is sorted into the endosomes via endocytosis for lysosomal degradation, thus terminating the growth factor signaling as a crucial feedback mechanism to prevent over-proliferation [6]. Here, Zhao et al., made an unexpected finding that CDC34 enhances EGFR signaling by inhibiting EGFR from ubiquitylation and degradation. Mechanistically, CDC34 via its N-terminus binds to the C-terminal intracellular domain of EGFR to directly compete with c-Cbl for EGFR binding, therefore preventing c-Cbl-mediated EGFR polyubiquitylation and subsequent lysosomal degradation. Thus, in contrast to its well-known proteolytic-promoting activity, CDC34 actually plays a previously unknown inhibitory role against EGFR ubiquitylation and degradation.

To determine the biological significance of CDC34-mediated EGFR protection, Zhao et al., used an siRNA-knockdown based approach to validate CDC34 as a promising lung cancer target in an EGFR dependent manner. Indeed, intranasal administration of the lentiviral particles, containing short hairpin RNA targeting CDC34, into the lungs effectively inhibited tumor growth in two mouse transgenic lung tumor models, driven respectively by EGFR mutants EGFR\textsuperscript{L858R} or by EGFR\textsuperscript{T790M}(DelE746-A750), commonly found in NSCLC. At the present time, there is no pharmacological approach available to further validate CDC34 as a lung target, although CC0651, a small molecule was reported, that selectively inhibited CDC34 by trapping the weak interaction between ubiquitin and the donor site of CDC34 [9]. However, it is unlikely that this small molecule would be effective to directly disrupt the protein-protein interaction of CDC34-EGFR.

Overall, the finding presented in this study provides a novel mechanism by which CDC34 positively regulates EGFR-mediated oncogenic signaling via competitive inhibition of c-Cbl mediated EGFR ubiquitylation and degradation, leading to EGFR stabilization.
Using both in vitro cell culture and in vivo mouse models, the authors clearly showed that CDC34 is indeed an attractive anti-lung cancer target. Thus, the study is highly significant with translational implications. Along the same vein, future studies should be undertaken in two directions. First, to further validate CDC34 as a lung cancer target, the mouse models should be generated with conditional knockout or transgenic expression of CDC34 in the lung alone or in combination with EGFR transgenic mouse models to determine tumor promoting role of CDC34 in a manner dependent of EGFR under “more” physiological conditions. Secondly, when validated, drug discovery efforts should be undertaken to identify small molecules that specifically bind to CDC34. Although it is anticipated that these small molecules would not be able to disrupt the CDC34-EGFR binding—an “undruggable” target, the PROTAC (proteolysis-targeting chimeras) strategy [10] can be employed to hook small molecule to cullin-RING ligase to directly target CDC34 for degradation. Discovery and development of these PROTAC compounds would have unique applications for the treatment of lung cancer with overexpressed CDC34 and EGFR.

Declaration of Competing Interest

The authors declare no conflict of interest.

Acknowledgments

The authors apologize to the many researchers whose work is not specifically referenced due to space limitations. This work was partly supported by the National Key R&D Program of China (2016YFA0501800) (YS), and the Chinese Scholarship Fund (ZSZ).

References

[1] Goebel MG, Yochem J, Jentsch S, McGrath JP, Varshavsky A, Byers B. The yeast cell cycle gene CDC34 encodes a ubiquitin-conjugating enzyme. Science (New York, NY) 1988;241(4871):1331–5.
[2] Tanaka K, Kondoh N, Shuda M, et al. Enhanced expression of mRNAs of antisercretory factor-1, gp96, DAD1 and CDC34 in human hepatocellular carcinomas. Biochim Biophys Acta 2001;1536(1):1–12.
[3] Price GR, Armes JE, Ramus SJ, et al. Phenotype-directed analysis of genotype in early-onset, familial breast cancers. Pathology 2006;38(6):520–7.
[4] Xinchun Zhao GW, Wen Zheseng, Zhou Yongchun, Hu Qian, Zhang Bin, Qi Liwei, et al. Systematic identification of CDC34 that functions to stabilize egfr and promote lung carcinogenesis. EBioMedicine 2020 https://doi.org/10.1016/j.ebiom.2020.102689.
[5] Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010;141(7):1117–34.
[6] Endres NF, Das R, Smith AW, et al. Conformational coupling across the plasma membrane in activation of the EGF receptor. Cell 2013;152(3):543–56.
[7] Thien CB, Langdon WY. Cbl: many adaptations to regulate protein tyrosine kinases. Nat Rev Mol Cell Biol. 2001;2(4):294–307.
[8] Umebayashi K, Stenmark H, Yoshimori T. Ub4c/5 and c-Cbl continue to ubiquitinate EGF receptor after internalization to facilitate polyubiquitination and degradation. Mol. Biol. Cell 2008;19(8):3454–62.
[9] Ceccarelli DF, Tang X, Pelletier B, et al. An allosteric inhibitor of the human CDC34 ubiquitin-conjugating enzyme. Cell 2011;145(7):1075–87.
[10] Schapira M, Calabrese MF, Bullock AN, Crews CM. Targeted protein degradation: expanding the toolbox. Nat Rev Drug Discov 2019;18(12):949–63.